66254 Federal Register / Vol. 65, No. 214 / Friday, November 3, 2000 / Notices

will be available for listening in the Board’s

Freedom of Information Office, and copies

may be ordered for $6 per cassette by calling

202–452–3684 or by writing to: Freedom of

Information Office, Board of Governors of the

Federal Reserve System, Washington, DC

20551.

CONTACT PERSON FOR MORE INFORMATION:

Lynn S. Fox, Assistant to the Board,

202–452–3204.

SUPPLEMENTARY INFORMATION: You may

call 202–452–3206 for a recorded

announcement of this meeting; or you

may contact the Board’s Web site at

http://www.federalreserve.gov for an

electronic announcement. (The Web site

also includes procedural and other

information about the open meeting.)

Dated: November 1, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–28346 Filed 11–1–00; 10:55 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of

Governors of the Federal Reserve

System.

TIME AND DATE: Approximately 10:30

a.m., Wednesday, November 8, 2000,

following a recess at the conclusion of

the open meeting.

PLACE: Marriner S. Eccles Federal

Reserve Board Building, 20th and C

Streets, NW., Washington, DC 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED: 

1. Personnel actions (appointments,

promotions, assignments,

reassignments, and salary actions)

involving individual Federal Reserve

System employees.

2. Any matters carried forward from a

previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION:

Lynn S. Fox, Assistant to the Board,

202–452–3204.

SUPPLEMENTARY INFORMATION: You may

call 202–452–3206 beginning at

approximately 5 p.m. two business days

before the meeting for a recorded

announcement of bank and bank

holding company applications

scheduled for the meeting; or you may

contact the Board’s Web site at http://

www.federalreserve.gov for an

electronic announcement that not only

lists applications, but also indicates

procedural and other information about

the meeting.

Dated: November 1, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–28347 Filed 11–1–00; 10:56 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Dermatologic and Ophthalmic Drugs

Advisory Committee; Notice of

Meeting; Correction

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug

Administration (FDA) is correcting a

notice that appeared in the Federal

Register of October 19, 2000 (65 FR

62722). The notice announced a meeting

of the Dermatologic and Ophthalmic

Drugs Advisory Committee, which was

scheduled for November 16, 2000. The

document was published with an error.

This document corrects that error.

FOR FURTHER INFORMATION CONTACT:

Anita Prout, Committee Management

Office (HFA–306), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–5503.

SUPPLEMENTARY INFORMATION: In FR Doc.

00–26787, appearing on page 62722 in

the Federal Register of Thursday,

October 19, 2000, the following

correction is made:

1. On page 62722, in the first column,

under the ‘‘Location’’ caption, ‘‘Holiday

Inn, Grand Ballroom, Two Montgomery

Village Ave., Gaithersburg, MD.’’ is

corrected to read ‘‘CDER Advisory

Committee, conference room 1066, 5630

Fishers Lane, Rockville, MD.’’

Dated: October 31, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–28349 Filed 11–01–00; 2:45 pm]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Clinical Chemistry and Clinical

Toxicology Devices Panel of the

Medical Devices Advisory Committee;

Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: Clinical

Chemistry and Clinical Toxicology

Devices Panel of the Medical Devices

Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on November 13, 2000, 10 a.m. to

4:30 p.m., and November 14, 2000, 8:30

a.m. to 4 p.m.

Location: Hilton, Salons C, D, and E,

620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Veronica J. Calvin,

Center for Devices and Radiological

Health (HFZ–440), Food and Drug

Administration, 2098 Gaither Rd.,

Rockville, MD 20850, 301–594–1243, or

FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572

in the Washington, DC area), code

12514. Please call the Information Line

for up-to-date information on this

meeting.

Agenda: On November 13, 2000, the

committee will discuss two draft

guidances: ‘‘Guidance for Prescription

Use Drugs of Abuse Assays Premarket

Notifications’’ and ‘‘Over the Counter

(OTC) Screening Tests for Drugs of

Abuse: Guidance for Premarket

Notifications.’’ The prescription use

guidance will be available to the public

on the Internet at http://www.fda.gov/

cdrh/ode/odecl052.html and supersedes

the document entitled ‘‘Review Criteria

for Assessment of In Vitro Diagnostic

Devices for Drugs of Abuse Assays

Using Various Methodologies.’’ The

OTC use guidance will be available to

the public on the Internet at http://

www.fda.gov/cdrh/ode/91.html and

supersedes the document entitled

‘‘Guidance for Premarket Submissions

for Kits for Screening Drugs of Abuse To

Be Used by the Consumer.’’ Draft

questions for the committee regarding

these guidances will be available to the

public on the Internet at http://

www.fda.gov/cdrh/panelmtg.html. On

November 14, 2000, the committee will

discuss and make recommendations on

a premarket notification (510(k)) for a

first-of-a-kind prescription use

screening device for heroin in human

hair.

Procedure: On November 13, 2000,

from 10 a.m. to 4:30 p.m., and on

November 14, 2000, from 9 a.m. to 4

p.m., the meeting is open to the public.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the